التفاصيل البيبلوغرافية
| العنوان: |
CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges. |
| المؤلفون: |
Rendo, Matthew J, Joseph, Jacinth J, Phan, Liem Minh, DeStefano, Christin B |
| المصدر: |
Blood & Lymphatic Cancer: Targets & Therapy; Aug2022, Vol. 12, p119-136, 18p |
| مصطلحات موضوعية: |
MULTIPLE myeloma, T cells, CHIMERIC antigen receptors, HEMATOLOGIC malignancies, CANCER cells |
| مستخلص: |
The therapeutic landscape of multiple myeloma (MM) has benefited from an emergence of novel therapies over the last decade. By inducing T-cell kill of target cancer cells, chimeric antigen receptor (CAR) T-cell therapies have improved outcomes of patients with hematologic malignancies. B-cell maturation antigen (BCMA) is the current target antigen of choice for most CAR T-cell products under investigation for MM. However, their shortcomings deal with logistical and clinical challenges, including limited availability, manufacturing times, and toxicities. This article provides an overview of recently developed and investigational CAR T-cell therapies for MM, highlighting current evidence and challenges. [ABSTRACT FROM AUTHOR] |
|
Copyright of Blood & Lymphatic Cancer: Targets & Therapy is the property of Dove Medical Press Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder